The Underdog That Just Knocked Out a $13 Billion Giant

It's the difference between cutting off a factory's power supply versus intercepting every truck leaving the loading dock. Both reduce delivery, but only one catches the trucks that have their own generators.

The Skin Question Is Still Open

Bimzelx's joint victory was clear. The skin story is murkier. A key secondary endpoint combined ACR50 with PASI100 (complete skin clearance) at Week 16. Bimzelx posted 33.5% versus 24.4% for Skyrizi, a numerical advantage. But it didn't reach statistical significance in the study's hierarchical testing framework (nominal p=0.0800).

That matters because Skyrizi's bread and butter has always been skin. AbbVie can argue that while Bimzelx won the joint fight, the overall "skin plus joints" picture is less definitive. Expect that talking point on the next earnings call.

On safety, the two drugs looked broadly similar. Overall side effects hit 57% of Bimzelx patients versus 52% on Skyrizi. Serious side effects were actually lower with Bimzelx (1.8% vs. 2.9%). The expected trade-off: mild yeast infections (candidiasis) were more common with Bimzelx, a known IL-17 class effect. None were serious, none systemic, and none caused patients to stop treatment.

A $13 Billion Market Just Got More Interesting

The global psoriatic arthritis treatment market sits at roughly $11 to $13 billion in 2025, growing at around 9% annually. Biologics account for more than half of that spending. Within the biologic world, TNF inhibitors like Humira still hold the largest chunk by volume, but they're shrinking thanks to biosimilar competition.

The real war is between IL-17 and IL-23 inhibitors for the non-TNF crown. And until now, momentum had been shifting toward IL-23. Rheumatologists loved Skyrizi's convenient dosing (every 12 weeks) and sterling safety profile. Dermatologists loved its skin clearance rates. AbbVie's commercial machine was doing what AbbVie's commercial machine always does.

BE BOLD throws a wrench into that narrative. For patients where joint control is the priority, particularly those with significant enthesitis, dactylitis, or axial symptoms, UCB now has the only head-to-head superiority data in the category. That's a powerful card to play in formulary negotiations and physician education.

What This Means for the Competitive Chessboard

Bimzelx was already having a moment. The drug crossed €2.2 billion in 2025 sales, more than tripling its prior-year revenue. It's approved across psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa.

The BE BOLD win adds fuel to an already hot franchise. It also puts pressure on Novartis (Cosentyx) and Eli Lilly (Taltz), the two established IL-17A inhibitors. Neither has head-to-head PsA superiority data against an IL-23 inhibitor. Bimzelx's dual IL-17A/F mechanism gives it a theoretical edge within its own class, and now there's clinical evidence to back it up.

For AbbVie, the damage is probably containable. Skyrizi's biggest revenue drivers are psoriasis and inflammatory bowel disease, not PsA. Analysts are unlikely to slash total Skyrizi forecasts over a single indication. But at the margins, especially among rheumatologists choosing a biologic for joint-dominant disease, share will shift.

Janssen's Tremfya (guselkumab), the other major IL-23 in PsA, catches indirect fire too. No head-to-head data against Bimzelx exists, but the class narrative now tilts toward IL-17A/F for joint outcomes.

The Bigger Picture

For years, the treatment algorithm in psoriatic arthritis has been vibes-based as much as evidence-based. TNF first because we've used it longest; then pick IL-17 or IL-23 depending on whether the patient's joints or skin are worse. Comorbidities like inflammatory bowel disease (where IL-17 can be risky) or axial disease (where IL-23 is weak) nudge the decision further.

BE BOLD doesn't rewrite the entire playbook. IL-23 inhibitors still have important niches: patients with IBD risk, those who value infrequent dosing, and cases where skin is the dominant problem. But for the substantial population of PsA patients whose joints are screaming, UCB just handed rheumatologists a data-backed reason to reach for Bimzelx first.

Full secondary endpoint data, including longer-term joint responses and detailed skin outcomes, are expected later in 2026. That's when we'll know whether this is a moment or a movement.

One Blood Draw. Fifty Cancers. The $689 Bet on Finding Them Early.

Exact Sciences launched Cancerguard, a $689 blood test that screens for 50+ cancer types from a single draw. It's a massive bet on liquid biopsy screening, but the mortality data gap and lack of FDA approval raise big questions about what "early detection" really means in practice.